NMN and NR Compounding Legal Status: FDA Rules, Dietary Supplement Classification, and What Patients Need to Know

Why the FDA Excluded NMN from the Dietary Supplement Definition

The FDA's November 2022 decision hinged on a provision in the Dietary Supplement Health and Education Act (DSHEA) of 1994. Under DSHEA, a substance that was first authorized for investigation as a new drug (IND) before it was marketed as a dietary supplement cannot be sold as a supplement, unless the Secretary of Health and Human Services issues a waiver. The FDA determined that NMN met this exclusion criterion because an IND for NMN was filed before NMN was commercially marketed as a supplement in the United States 1.

This ruling did not make NMN illegal to possess or consume. It made NMN illegal to market as a "dietary supplement" under federal law. The distinction matters. Products labeled as dietary supplements receive a specific regulatory framework under DSHEA, including structure/function claims, Good Manufacturing Practice (GMP) requirements, and mandatory adverse event reporting. Without that classification, NMN products sold online occupy a gray zone.

Metro International Biotech, the company behind the IND filing, had been developing NMN (designated MIB-626) as a potential anti-aging therapeutic. The FDA's response letter confirmed that the agency viewed the IND as predating commercial supplement sales, a sequence that triggers the statutory exclusion. Several supplement trade groups, including the Natural Products Association, disputed the FDA's timeline and filed formal objections 2.

The FDA has not yet taken enforcement action against NMN supplement sellers. Products remain widely available on e-commerce platforms as of mid-2026. That availability does not indicate legality. It reflects enforcement discretion.

How NR (Nicotinamide Riboside) Differs Legally from NMN

NR has a clearer regulatory path. ChromaDex, the company behind the branded ingredient Niagen, established NR as a New Dietary Ingredient (NDI) with the FDA in 2013 and obtained self-affirmed Generally Recognized as Safe (GRAS) status through an independent expert panel 3. Because NR was marketed as a dietary supplement before any IND was filed for it, the DSHEA exclusion that snagged NMN does not apply.

This means NR can legally be sold as a dietary supplement in the United States. It can carry structure/function claims (with appropriate disclaimers). It can be manufactured under 21 CFR Part 111 GMP rules. NMN cannot do any of these things under the FDA's current position.

The biological distinction between the two molecules is small. Both are NAD+ precursors. NR is converted to NMN inside the cell by nicotinamide riboside kinases (NRK1 and NRK2), and NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNAT enzymes) 4. The regulatory distinction, however, is binary: one is a lawful supplement, the other is not.

"The pharmacological difference between NR and NMN is minimal at the cellular level, but their regulatory trajectories are completely different," noted Dr. Charles Brenner, the biochemist who discovered NR's vitamin function, in a 2023 commentary published in Nature Metabolism 5.

Compounding Pharmacy Rules for NMN and NR

Neither NMN nor NR appears on the FDA's list of bulk drug substances that can be used in compounding under Section 503A (traditional compounding by state-licensed pharmacies) or Section 503B (outsourcing facilities). For a substance to be eligible for compounding, it must meet one of several conditions: it must be a component of an FDA-approved drug, it must appear on the FDA's positive list of bulk drug substances, or it must be the subject of an applicable United States Pharmacopeia (USP) or National Formulary monograph 6.

NMN meets none of these conditions. There is no FDA-approved NMN drug product. NMN does not appear on the FDA's bulk drug substances list under evaluation or approved for 503A or 503B use. The USP has not published a monograph for NMN as a pharmaceutical ingredient.

Compounding pharmacies that prepare NMN formulations (capsules, sublingual tablets, IV preparations) operate outside the FDA's compounding framework. Patients receiving NMN from compounding pharmacies should understand that these products have not been evaluated by the FDA for safety, efficacy, or manufacturing quality. The legal risk falls primarily on the pharmacy, not the patient, but product quality cannot be guaranteed without FDA oversight.

For NR, the same compounding restrictions apply. Despite its lawful supplement status, NR is not approved as a drug and lacks the regulatory prerequisites for pharmacy compounding.

What the Clinical Evidence Actually Shows

The most cited NMN clinical trial is the 2021 study by Yoshino et al. published in Science. This randomized, placebo-controlled trial enrolled 25 postmenopausal women with prediabetes and administered 250 mg/day of NMN for 10 weeks. The NMN group showed a 25% improvement in skeletal muscle insulin sensitivity measured by hyperinsulinemic-euglycemic clamp, while the placebo group showed no change 7.

That result is promising. It is also from a trial of 25 people. No Phase III NMN trial has been completed. No NMN trial has measured hard clinical endpoints like cardiovascular events, cancer incidence, or mortality.

A 2022 study by Yi et al. randomized 66 healthy adults to NMN (300, 600, or 900 mg/day) or placebo for 60 days. Walking endurance improved in the 600 mg and 900 mg groups, and blood NAD+ levels increased dose-dependently. No serious adverse events were reported 8.

For NR, the evidence base is broader. A 12-week trial by Martens et al. (2018) in 24 lean, healthy older adults found that NR at 1,000 mg/day reduced systolic blood pressure by 3.3 mmHg and reduced aortic stiffness compared to placebo 9. Larger NR trials are ongoing, including studies in heart failure (NCT03423342) and Alzheimer's disease.

"We have plausible mechanism, we have early-phase signal, but we do not have the large-scale evidence that would support a drug approval," said Dr. Shin-ichiro Imai, a professor at Washington University School of Medicine and senior author of the Yoshino trial, in a 2022 interview with Cell Metabolism 10.

Safety Data and Known Risks

Short-term safety data for NMN in humans is reassuring but limited. Across published trials (doses ranging from 100 mg to 1,250 mg/day, durations from single-dose pharmacokinetic studies to 12 weeks), no serious adverse events have been attributed to NMN 7 8. Common mild effects include gastrointestinal discomfort, mild flushing, and headache.

For NR, the safety dataset is larger. A systematic review by Mehmel et al. (2020) covering multiple human trials concluded that NR at doses up to 2,000 mg/day for up to 12 weeks was well tolerated, with the most common side effects being nausea, fatigue, and headache at higher doses 11.

Three safety concerns deserve attention regardless of the molecule:

NAD+ and cancer cell metabolism. NAD+ is required for DNA repair, but it is also required for rapid cell proliferation. Preclinical data in mouse models has shown that NAD+ supplementation can accelerate tumor growth in certain cancer types 12. No human trial has demonstrated this effect, but patients with active malignancies should discuss NAD+ precursor use with their oncologist.

Drug interactions. NMN and NR may interact with medications that affect NAD+ metabolism, including certain chemotherapeutics (NAMPT inhibitors like FK866) and PARP inhibitors (olaparib, niraparib). Concurrent use could theoretically reduce the efficacy of these drugs by restoring the NAD+ pool they are designed to deplete 13.

Product quality variability. Because NMN exists in a regulatory gray area, product quality varies enormously. Independent testing by ConsumerLab (2023) found that several NMN products contained less than 50% of their labeled dose. Without FDA-mandated GMP compliance for these products, contamination and underdosing are real risks.

Current Legal Challenges and Pending Regulatory Action

Several parallel legal and regulatory proceedings could change NMN's status:

The Natural Products Association filed a citizen petition in 2023 asking the FDA to reverse its NMN exclusion, arguing that NMN was marketed as a supplement before the Metro International Biotech IND was filed. The FDA has not issued a final response to this petition as of May 2026 14.

Congressional action is also possible. The Dietary Supplement Regulatory Reform Act, introduced in the 118th Congress, included provisions that would narrow the IND preclusion clause in DSHEA. The bill did not pass but was reintroduced in the 119th Congress. If enacted, it could restore NMN's supplement eligibility.

Meanwhile, Metro International Biotech's clinical program for MIB-626 continues. If MIB-626 receives FDA approval as a prescription drug, NMN would become available through traditional pharmacy channels but likely at significantly higher cost than current supplement pricing. The company completed Phase II trials in 2023, but Phase III enrollment timelines have not been publicly disclosed 15.

State-level enforcement adds another variable. Some state pharmacy boards have issued guidance letters warning compounding pharmacies against preparing NMN formulations. Others have remained silent. Enforcement is inconsistent.

What Patients Should Know Before Purchasing NMN or NR

Patients considering NAD+ precursor supplementation face a practical decision shaped by regulatory reality.

NR is the legally straightforward option. Products from manufacturers with NDI notification and GRAS determination (such as ChromaDex's Niagen) are manufactured under dietary supplement GMP and carry third-party testing certifications. Doses of 300 to 1,000 mg/day have the most clinical support 9.

NMN products are still widely sold but lack the regulatory protections of the supplement framework. Patients who choose NMN should look for products with third-party certificates of analysis (COA) from ISO 17025-accredited laboratories, test results for heavy metals and microbial contamination, and transparent manufacturing location disclosure.

No NAD+ precursor is FDA-approved to treat, cure, or prevent any disease. Clinicians who recommend these products should document the discussion, note the off-label or supplement nature of the recommendation, and monitor patients with baseline and follow-up NAD+ metabolome panels where available.

The Endocrine Society has not issued a formal clinical practice guideline on NAD+ precursor therapy 16. The American Academy of Anti-Aging Medicine (A4M) includes NAD+ optimization in its fellowship curriculum but has not published a consensus statement with specific dosing protocols.

Patients taking PARP inhibitors, undergoing active chemotherapy, or with a history of NAD+-dependent malignancies should avoid NAD+ precursors until prospective safety data in these populations is available.